Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial
CHICAGO-It may be possible to identify non-small-cell lung cancer (NSCLC) patients with a high or low risk of relapse after surgery, according to findings presented at ASCO 2008 (abstract 7501).
CHICAGO-It may be possible to identify non-small-cell lung cancer (NSCLC) patients with a high or low risk of relapse after surgery, according to findings presented at ASCO 2008 (abstract 7501).
By analyzing data from a phase II trial of the investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (GlaxoSmithKline) in resected NSCLC, Johan F. Vansteenkiste, MD, PhD, of Catholic University, Leuven, Belgium, and colleagues were able to identify a gene signature predicting good prognosis. Overall, in the study, MAGE-A3 reduced the relative risk of recurrence by 25%, but in the population with a predicted low risk (gene signature positive), the risk reduction with MAGE-A3 was 43%.
The gene signature will be prospectively evaluated in the ongoing phase III MAGRIT study in MAGE-A3-positive NSCLC patients (stage Ib, II, and IIIA) who have undergone complete surgical resection, Dr. Vansteenkiste said.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
